On Oct 08, major Wall Street analysts update their ratings for $MBX Biosciences (MBX.US)$, with price targets ranging from $30 to $44.
J.P. Morgan analyst Jessica Fye initiates coverage with a buy rating, and sets the target price at $30.
Jefferies analyst Michael Yee initiates coverage with a buy rating, and sets the target price at $35.
Guggenheim analyst Seamus Fernandez initiates coverage with a buy rating, and sets the target price at $44.
Stifel analyst Annabel Samimy initiates coverage with a buy rating, and sets the target price at $40.
Furthermore, according to the comprehensive report, the opinions of $MBX Biosciences (MBX.US)$'s main analysts recently are as follows:
MBX Biosciences is focused on creating peptide therapies aimed at targets within the endocrine/metabolic sector, utilizing its unique Precision platform to potentially enhance drug profiles. The company's primary candidate, MBX 2109, is considered a significant initial endeavor to address chronic hypoparathyroidism, with a Phase II trial currently in progress and anticipated top-line results in the third quarter of 2025. It is believed that the company's stock offers a compelling opportunity prior to a series of important milestones and events poised to potentially validate and increase the value of MBX's drug pipeline over the upcoming year.
MBX Biosciences is deemed to have a strong potential for success with MBX-2109 in Phase II for parathyroid hormone treatment. The company's robust scientific peptide platform is recognized for its ability to extend the duration of therapy and enhance efficacy for peptides targeting PTH and obesity. Additionally, the current valuation of the company's shares is viewed as attractive.
MBX Biosciences is recognized for its 'robust and productive' technology platform focused on precision endocrine peptides aimed at rare endocrine and metabolic disorders, which present significant market opportunities. The company has enhanced pharmaceutical attributes to ensure optimal therapeutic application, including maintaining peptide integrity, minimizing variability, prolonging action duration, and crucially, lessening the frequency of injections.
The initiation of coverage on MBX Biosciences comes with a positive outlook based on the potential presented by the company's development of longer-acting peptides aimed at clinically de-risked targets within endocrine and broader metabolic diseases. Key to this perspective is the company's lead compound, MBX 2109, which is a unique once-weekly peptide designed for a significant market opportunity in post-bariatric hypoglycemia.
Here are the latest investment ratings and price targets for $MBX Biosciences (MBX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月8日，多家華爾街大行更新了$MBX Biosciences (MBX.US)$的評級，目標價介於30美元至44美元。
摩根大通分析師Jessica Fye首次給予買入評級，目標價30美元。
富瑞集團分析師Michael Yee首次給予買入評級，目標價35美元。
Guggenheim分析師Seamus Fernandez首次給予買入評級，目標價44美元。
斯迪富分析師Annabel Samimy首次給予買入評級，目標價40美元。
此外，綜合報道，$MBX Biosciences (MBX.US)$近期主要分析師觀點如下：
MBX生物科學專注於創建肽治療方案，旨在瞄準內分泌/代謝領域的目標，利用其獨特的Precision平台，可能增強藥物概況。該公司的主要候選藥物MBX 2109被認爲是解決慢性甲狀旁腺功能減退症的重要初步努力，目前正在進行II期試驗，並預計2025年第三季度公佈首要結果。人們相信，在一系列重要里程碑和事件發生之前，該公司的股票提供了一個引人注目的機會，有望驗證和增加MBX藥物管道的價值。
MBX生物科學被認爲在甲狀旁腺素治療II期中擁有成功的強大潛力。該公司強大的科學肽平台以其延長療程和提高針對PTH和肥胖的肽治療效果而聞名。此外，該公司股票的當前估值被視爲有吸引力。
MBX生物科學以其專注於罕見內分泌和代謝紊亂的精密內分泌肽技術平台而聞名，這些疾病呈現出重要的市場機會。該公司提升了藥品屬性，以確保最佳的治療應用，包括維持肽的完整性，減少變異性，延長作用持續時間，關鍵的是減少注射頻率。
對MBX生物科學的覆蓋起始基於該公司開發針對內分泌和更廣泛代謝性疾病內臨床風險降低目標的長效肽的潛力呈現出積極的展望。關鍵在於該公司的主導compound MBX 2109，這是一個獨特的一週一次肽，旨在市場機會巨大的術後胃減肥性低血糖中使用。
以下爲今日4位分析師對$MBX Biosciences (MBX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
